FDA reviewers now expect raw datasets and R packages to run their own statistical validation models. This structural change requires pharma teams to overhaul their submission pipelines, shifting the true value of clinical AI from simple operational speed to scientific breakthroughs.
FDA reviewers now want raw datasets and functional R packages to conduct independent, internal analyses rather than just reading static submission documents.
Machine learning can characterize complex disease mechanisms, isolate optimal patient subgroups, and design trial frameworks that were previously impossible to conceptualize.
Modeling highly accurate artificial patient data lets programmers write, test, and debug their CDISC-compliant dataset pipelines long before the first patient is enrolled.
Universities no longer prioritize teaching legacy tools like SAS. New hires enter the market requiring modern, governed platforms that match how they already code.
Accumulating efficacy and safety data continuously allows sponsors to optimize dosing, re-estimate sample sizes mid-course, and significantly compress regulatory timelines.
AI can supplement data processing, but it will never replace a multidisciplinary team of scientists choosing the correct endpoints, comparators, and statistical methodologies upfront.
Eric Gibson, SVP of Advanced Quantitative Sciences, oversees 1,200 researchers at Novartis. Drawing on the massive scale of his organization, he tackles a central question facing the entire pharmaceutical industry: what does this current wave of clinical AI actually mean, and why does it feel different from past technological shifts?
The answer is divided into two parts. First is the operational reality. The regulatory landscape has permanently changed. FDA reviewers are highly trained quantitative scientists who want raw data and a suite of R packages to generate their own insights. Drug development teams must build open-source, reproducible pipelines to align with this regulatory direction.
Second is the scientific upside. Gibson highlights Novartis’s five-year collaboration with Oxford University on multiple sclerosis, where machine learning algorithms analyzed a multimodal dataset of clinical records, fluid biomarkers, and a quarter-million brain MRIs. The AI successfully isolated eight distinct disease states and identified the transitional biology driving disability progression. This discovery prompted regulatory meetings with the FDA and EMA to redefine how MS trials are designed. For pharma organizations targeting this level of innovation, establishing a governed statistical computing environment is the foundational step.
